ALNY Q2 2024 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$660M+107.0% YoY

Gross Profit

$591M89.6% margin

Operating Income

$49M7.4% margin

Net Income

-$17M-2.6% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

+33.5%

Cash Flow

Operating Cash Flow

$124M

Free Cash Flow

$116M

Stock-Based Comp.

$89M

Balance Sheet

Total Assets

$4.0B

Total Liabilities

$4.0B

Stockholders' Equity

-$3M

Cash & Equivalents

$968M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$660M	$319M	+107.0%
Gross Profit	$591M	$233M	+153.3%
Operating Income	$49M	-$230M	+121.2%
Net Income	-$17M	-$276M	+93.9%

Revenue Segments

Product

$410M75%

ONPATTRO

$77M14%

GIVLAARI

$62M11%

Geographic Segments

UNITED STATES

$148M65%

Europe

$57M25%

Non-US Or Europe

$25M11%